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ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN
POLAND—OUT–PATIENT VIEWPOINT
Czech M1, Horoszewska M2, Pachocki R1
1Servier Polska, Warsaw, Poland; 2Warsaw University of Technology,
Warsaw, Poland
Fast and dynamic development of medicine and pharmacy is
linked not only with efﬁcacy and safety of drugs but also with
their cost–effectiveness, especially when patients’ co-payment
systematically increases. OBJECTIVES: To investigate the recog-
nition of the term “pharmacoeconomics” by patients of an open
pharmacy and the role of economic aspects in decision making
concerning drug purchases. METHODS: A total of 270 patients
(170 suffering from chronic and 100 from acute diseases) were
interviewed (18 questions with a 5 level weighted / validity scale).
RESULTS: A total of 67% of respondents were able to deﬁne
(more or less precisely) the term “pharmacoeconomics”. Thirty
percent (30%) of patients treated acutely and eight 8% chroni-
cally were unable to pay for their prescriptions (level of co-
payment too high), which decreases their compliance (different
factors also apply). Price elasticity of demand was low: 67 out
of 100 treated chronically and 76 out of 100 treated acutely
would not have a prescription made up if the price of a drug
increased by 50%. On the other hand, 88% and 92% of patients
treated for chronic and acute diseases respectively would ﬁnd
sources of ﬁnance if non-treatment led to serious health conse-
quences and 93% of respondents would pay more for a drug if
they were sure it was absolutely safe. Forty percent (40%) of
respondents declared that they would like to use only drugs
which make them able to work, 81% prefer to take effective but
sometimes expensive drugs in order to shorten hospitalization
time. CONCLUSIONS: Elements of cost-effectiveness, relation-
ship between the price of a drug and its effectiveness and safety
as well as different cost components linked to a medical condi-
tion remain within the scope of interest of patients purchasing
drugs in pharmacy.
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PREFERENCES MATTER: UNDERSTANDING DEMAND FOR
VOLUNTARY HEALTH INSURANCE
De Allegri M1, Sanon M2, Bridges JFP1, Sauerborn R1
1University of Heidelberg, Heidelberg, Germany; 2Centre de
Recherche en Sante’ de Nouna, Nouna, Burkina Faso
OBJECTIVES: The aim of this study was to explore individual
and community factors affecting the decision making process
leading to purchase of voluntary health insurance among a rural
community in sub-Saharan Africa. Such intervention is crucial in
the context given that, by pooling resources and risks across a
community, it can increase equitable access to health care ser-
vices and reduce health disparities. METHODS: The study used
qualitative research methods to understand consumers’ prefer-
ences in relation to their decision to purchase voluntary health
insurance. This approach was considered preferable to quanti-
tative methods traditionally used in demand analysis because of
its potential to capture the complexity involved. Thirty-two
respondents were selected for an individual in-depth interview
using a stratiﬁed sampling design based on insurance status, dis-
tance to health facility and socio-economic status. All interviews
were tape recorded, fully translated and transcribed, analyzed
and triangulated by two independent researchers using Atlas.ti
software. Data from eight focus group discussions provided an
additional valuable source of triangulation. RESULTS: Partici-
pants, regardless of insurance status, understood the insurance
potential to decrease health inequalities by facilitating access to
Health Care services. They justiﬁed their decision to purchase or
not to purchase insurance in relation to their preference regard-
ing speciﬁc elements of the scheme, including the enrollment
unit, the beneﬁt package, the management structure, the
payment modalities, and the timing of the enrollment campaign.
CONCLUSIONS: The use of qualitative methods led to a thor-
ough investigation of consumers’ preferences. It allowed to for-
mulate clear and concise policy recommendations to be used to
redirect the scheme design. The qualitative approach proved to
be a valuable tool for understanding consumers’ preferences in
relation to the formulation of health policy suggesting that in
many circumstances, it is to be preferred to traditional quanti-
tative methods as an evaluation technique.
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PHARMACOECONOMICS INTRODUCTION IN THE CREATION
OF POSITIVE DRUG LIST IN BULGARIA
Petrova GI GIP1, Benisheva TVB2, Ivanova AD1
1Faculty of Pharmacy, Soﬁa, Bulgaria; 2Ministry of Health, Soﬁa,
Bulgaria
OBJECTIVES: To analyze the effect of the introduction of phar-
macoeconomics evaluations in the creation of a positive drug list
in Bulgaria. METHODS: Legislation analysis of the current 
regulation for the creation of positive drug lists and its impact
on the number of medicines proposed for reimbursement and
included in the list. RESULTS: Regulation for the creation of
positive drug lists was issued in 2002 in Bulgaria with the aim
to establish clear criteria for the selection of medicines for the
reimbursement practice and decrease the number of reimbursed
drugs. The medicines were separated into three main classes—
originators; medicines for which there is a therapeutic alterna-
tive but which have higher efﬁciency or less adverse drug events,
and generic medicines. For the ﬁrst two groups, producers were
asked to prepare pharmacoeconomic evaluation following pre-
viously established form. Out of the 3500 dosage forms regis-
tered in the country as prescription medicines, 2852 dossies were
submitted, of which 2477 dosage forms were included in the pos-
itive drug list (550 INN). Originators account for 63%, imported
generics for 19% and domestic generics for 18%. Excluded 
medicines compose 45% originators, 20% imported generics,
18% domestic generics. In comparison with previously existing
drug lists, the number of drugs did not decrease signiﬁcantly.
Main difﬁculties during the evaluation process were lack of phar-
macoeconomics analysis within the country, lack of national
pharmacoeconomic guidelines and changes in the companies
pricing policy. CONCLUSIONS: The introduction of pharma-
coeconomic evaluation during the process of the creation of a
positive drug list in Bulgaria did not decrease the number of
selected medicines but stimulate companies to start developing
evaluations within the country.
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MEDICINAL CANNABIS IN THE NETHERLANDS
Janse AFC, Breekveldt-Postma NS, Erkens JA, Herings RMC
PHARMO Institute, Utrecht,The Netherlands
OBJECTIVES: In The Netherlands, cannabis has been available
for medicinal purposes in pharmacies upon prescription by a
medical doctor since September 2003. This research was done to
study the characteristics of patients that start to use cannabis
from pharmacies. METHODS: A national enquiry was started
to identify all patients who were prescribed medicinal cannabis.
Patients were contacted by their pharmacist to ﬁll out a ques-
tionnaire. The questionnaire contained items about characteris-
tics of patients; complaints and morbidity; use of cannabis;
experiences with other cannabis products. Furthermore, history
of drug use was collected. RESULTS: In total, 200 patients
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returned a questionnaire whereas drug history was available for
175 of these patients. Sixty-seven percent (67%) of respondents
were female, and 60% of all respondents had used cannabis
before. The main indications for cannabis use were chronic pain
(72.5%) and muscle cramp/stiffness (53.0%). Among the
cannabis users, 42.0% suffered from multiple sclerosis and
11.0% were diagnosed with rheumatic diseases. The history of
drug use showed a relatively frequent use of analgesics (36.6%)
and psycholeptics (34.9%). Experiences with previous use of
other cannabis products indicated that concomitant drug use
could be decreased in 40.4% of the patients, remained the same
in 48.6% and increased in 0.9%; in total 10.1% did not use any
concomitant drugs. Most reported side effects of previous
cannabis products were lethargy (42.5%) and dry mouth
(38.1%). CONCLUSIONS: The main indications for prescrip-
tion of medicinal cannabis were chronic pain and muscle
cramp/stiffness; multiple sclerosis was the most frequently
reported disease. The majority of patients had used other
cannabis products before, resulting in a decrease in concomitant
drug use in a substantial number of patients. Legalization did
not cause an excessive increase of cannabis used, most likely to
be explained by the more expensive drugs in the pharmacy com-
pared to coffee shops.
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INTRODUCING THE ‘FOURTH HURDLE’ IN THE NEW
EUROPEAN UNION MEMBER STATES: THE CASE 
OF HUNGARY
Gulácsi L1, Boncz I2, Drummond MF3
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OBJECTIVES: This paper outlines the current development of
the “fourth hurdle” (i.e. requirement of effectiveness and cost-
effectiveness data for drug coverage policy decisions) in one of
the new European Union member states, describes the needs and
seeks to address some of the most important questions in this
ﬁeld. METHODS: The paper draws on international experiences
and discusses some issues that a given jurisdiction needs to con-
sider prior to introducing the “fourth hurdle” for pharmaceuti-
cals. RESULTS: The “fourth hurdle” is very relevant to the new
member states since many existing drugs are unevaluated and
many new, expensive drugs are becoming available. On the other
hand, the existing resources for health technology assessment,
including economic evaluation, are quite limited. CONCLU-
SIONS: The most important issue seems to be that the imple-
mentation of the “fourth hurdle” needs to be achieved in a way
consistent with the limited resources for health economics analy-
sis in the new member states. Speciﬁcally this means that, in
setting priorities for drugs to be evaluated, additional criteria
need to be applied. In particular, priority should be given to
assessing drugs that have been evaluated in other countries, since
this affords the opportunity to adapt existing studies or models
to the situation of the new European Union member states.
Opportunity exists to learn from experiences and mistakes in
other countries and to ﬁnd ways to make optimal use of evidence
produced elsewhere and processes, which are already thoroughly
tested. Given these restrictions, recommendations will be made
on how to implement results of economic evaluation, using
health economics as a tool to support reimbursement of medi-
cines as a case study.
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EFFECTS OF DEVOLUTION OF SUBSIDIES FOR
PHARMACEUTICALS IN SWEDEN
Bergstrom G, Karlberg I
Goteborg University, Gothenburg, Sweden
OBJECTIVES: In this study, the effects of devolution of subsi-
dies for pharmaceuticals from the state to the regional health
authorities—counties—in Sweden were studied. The aim of the
reform in 1998 was to cut the escalating costs associated with
risk sharing mechanisms on a national level as well as the third
party payer principles. METHODS: The documentation was
studied and the history of development and the current opinions
were analysed from interviews in nine counties, selected based
on their method of devolution. RESULTS: Two main principles
were found: either a population-based responsibility for costs;
family medicine in primary care was responsible for costs of
drugs classiﬁed as “basic” (80%) regardless of prescriber, in
addition hospital departments were responsible for “special
drugs” regardless of prescriber. The other model was a pre-
scriber-based responsibility; each unit of care was responsible for
costs of its own prescribing. CONCLUSIONS: Incentives for
cost containment are strongest in the prescriber-based models.
Integration of drug costs in overall Health Care costs, service to
patients and dialogue between providers are supported by the
population-based models.
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PROPER DRUG MANAGEMENT IN PHARMACY—THE 
ROLE OF PHARMACOECONOMICS AS PERCEIVED BY 
POLISH PHARMACISTS
Czech M1,Turczynski R2, Pachocki R1
1Servier Polska, Warsaw, Poland; 2Warsaw University of Technology,
Warsaw, Poland
On one hand, direct usage of pharmacoeconomic analyses in
contemporary pharmacy practice seems to be limited, on the
other hand correct communication with patients may beneﬁt
from promotion of rational pharmacotherapy, which stems from
both doctors’ decisions (prescribed drugs) and ﬁnancial abilities
of patients (especially when patient’s co-payment is high).
OBJECTIVES: To investigate the level of awareness among 
pharmacists concerning pharmacoeconomics in general, con-
ducting and application of pharmacoeconomic analyses, activi-
ties focused on proper drug management (out-patient
formularies, drug monitoring utilization systems, prescribing
behaviour), etc. METHODS: Managers of 50 randomly selected
pharmacies in Poland were interviewed. RESULTS: At the
moment, drug costs, experts’ opinion, personal opinion and drug
efﬁcacy are the most important sources of information. However,
in an ideal situation the order should be different: efﬁcacy, expert
opinions and costs. Lack of governmental agencies’ regulations
on pharmacoeconomic evaluations, limited access to standarised
cost data and low reliability of existing results of studies are
listed among the main drawbacks in application of pharma-
coeconomic study results. Wider use of pharmacoeconomics may
be due to the creation of national cost databases in Health Care
and introduction of transparent evaluation criteria. Societal and
patient’s viewpoint were indicated as the most appropriate where
87% of respondents declared the need to expand their knowl-
edge in the ﬁeld, 48% supported the idea of the creation of out-
patient formularies, 42% were opposed, 65% conﬁrmed the
necessity of introduction of central drug usage monitoring
systems, 65% of pharmacists claimed that they should inform
GP’s that their patients are unable to purchase a prescribed drug
(co-payment is too high, need for substitution) and 75% thought
that discussing economic aspects of treatment with patients was
